KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Receivables (2018 - 2025)

Twist Bioscience (TWST) has disclosed Receivables for 8 consecutive years, with $62.4 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 51.54% to $62.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.4 million through Dec 2025, up 51.54% year-over-year, with the annual reading at $60.9 million for FY2025, 64.82% up from the prior year.
  • Receivables for Q4 2025 was $62.4 million at Twist Bioscience, up from $60.9 million in the prior quarter.
  • The five-year high for Receivables was $62.4 million in Q4 2025, with the low at $2.3 million in Q3 2021.
  • Average Receivables over 5 years is $41.9 million, with a median of $42.5 million recorded in 2022.
  • The sharpest move saw Receivables crashed 91.45% in 2021, then skyrocketed 1769.66% in 2022.
  • Over 5 years, Receivables stood at $27.4 million in 2021, then skyrocketed by 81.52% to $49.7 million in 2022, then fell by 23.82% to $37.9 million in 2023, then rose by 8.71% to $41.2 million in 2024, then surged by 51.54% to $62.4 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $62.4 million, $60.9 million, and $50.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.